Campaigns blog
Find out how MS campaigners are making a difference across the UK.
Posts in Disease modifying drugs (DMDs)
New law could improve access to off-patent drugs
Posted on 06 Apr 2016 at 11:19AM by Emma Darkins
The Access to Medical Treatments (Innovations) Bill has now become law. This is an important milestone in our Treat Me Right campaign as it could improve access to repurposed off-patent drugs for people with MS.
One of the Act’s main clauses will introduce a database of innovative treatments including evidence about repurposed off-patent drugs.
The Risk Sharing Scheme - what does it mean for me?
Posted on 04 Apr 2016 at 3:29PM by Anonymous
What is the Risk Sharing Scheme?
The Risk Sharing Scheme (RSS) is a patient access scheme for treatments. It was set up in 2002 in response to a National Institute for Health and Care Excellence (NICE) decision that two licensed MS medicines were not cost effective and should not be made available on the NHS.
Why we patently need the Off-patent Drugs Bill
Posted on 17 Oct 2015 at 10:08PM by AnonymousPicture the scene: a researcher discovers that an old drug originally developed and patented for another condition can also be used to effectively treat multiple sclerosis. This is known as an “off-patent drug”. Clinical trials are conducted, and early results seem to confirm this too.
Effective treatments must remain available on NHS
Posted on 02 Apr 2015 at 11:17AM by Eleanor Brown
Data gathered by the Risk Sharing Scheme (RSS) over six years has proved that four treatments for relapsing remitting MS slow progression, and are cost effective.
How do new medicines get approved in England and Wales?
Posted on 25 Mar 2014 at 5:57PM by Robyn Casey
Before new medicines are made available in England, they undergo an appraisal by the National Institute for Health and Care Excellence (NICE).
We take a look at the appraisal proccess in England, what happens if a medicine is not recommended by NICE and how you can campaign to access treatments.
Putting a price on health
Posted on 06 Jan 2014 at 4:20PM by Robyn Casey
In 2010 the coalition government announced that a new system for assessing the cost of medicines, known as value-based pricing (VBP), would be introduced in England and Wales.
It was initially proposed to help increase access to medicines and improve innovation in the development of new drugs.
Categories
- Uncategorized (22)
- All UK (12)
- Alternative therapies (2)
- Bladder (1)
- Campaigns (25)
- Care (2)
- Disability benefits (32)
- Disease modifying drugs (DMDs) (6)
- DLA (2)
- Driving and DVLA (1)
Archive
- August 2011 (1)
- October 2011 (3)
- November 2011 (1)
- December 2011 (1)
- February 2012 (1)
- March 2012 (1)
- May 2012 (1)
- July 2012 (1)
- September 2012 (1)
- October 2012 (1)
